Stocks Overview

LAST PRICE
71.3600
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
28.5500/ 2
Ask / Lots
113.4600/ 1
Open / Previous Close
0.0000 / 71.3600
Day Range
---
52 Week Range
Low 56.4500
High 77.7200
Volume
---
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 70.35
Time	Volume	RDY
09:32 ET	3710	71.77
09:34 ET	100	71.87
09:36 ET	400	71.87
09:38 ET	200	71.93
09:39 ET	300	71.86
09:41 ET	500	71.86
09:43 ET	900	71.86
09:45 ET	2398	71.76
09:54 ET	200	71.84
09:56 ET	300	71.85
09:57 ET	200	71.86
09:59 ET	100	71.86
10:01 ET	100	71.835
10:03 ET	300	71.86
10:06 ET	500	71.88
10:08 ET	200	71.88
10:10 ET	600	71.8739
10:12 ET	683	71.76
10:15 ET	3606	71.8
10:17 ET	100	71.75
10:21 ET	100	71.79
10:24 ET	400	71.82
10:26 ET	100	71.82
10:28 ET	100	71.82
10:30 ET	200	71.83
10:32 ET	200	71.83
10:33 ET	200	71.81
10:35 ET	500	71.87
10:37 ET	300	71.87
10:42 ET	300	71.9
10:44 ET	500	71.91
10:46 ET	1000	71.83
10:50 ET	100	71.88
10:51 ET	831	71.795
10:53 ET	100	71.795
10:55 ET	1903	71.71
10:57 ET	535	71.74
11:00 ET	1100	71.71
11:02 ET	200	71.75
11:04 ET	879	71.78
11:06 ET	200	71.8
11:08 ET	500	71.79
11:09 ET	100	71.79
11:11 ET	500	71.79
11:13 ET	600	71.75
11:15 ET	200	71.75
11:18 ET	100	71.75
11:20 ET	1700	71.82
11:24 ET	900	71.75
11:26 ET	833	71.75
11:27 ET	100	71.785
11:29 ET	100	71.82
11:31 ET	200	71.82
11:33 ET	200	71.84
11:36 ET	1590	71.77
11:42 ET	200	71.8
11:44 ET	100	71.8
11:45 ET	500	71.8
11:47 ET	300	71.75
11:49 ET	200	71.8
11:51 ET	200	71.8
11:54 ET	100	71.765
11:56 ET	2017	71.765
11:58 ET	200	71.76
12:00 ET	400	71.7
12:05 ET	500	71.663
12:07 ET	787	71.64
12:09 ET	3034	71.61
12:12 ET	488	71.67
12:16 ET	500	71.69
12:20 ET	302	71.75
12:25 ET	200	71.73
12:27 ET	557	71.7
12:30 ET	714	71.7599
12:41 ET	808	71.608
12:45 ET	746	71.6
12:48 ET	223	71.6
12:50 ET	1100	71.51
12:56 ET	1112	71.56
01:01 ET	518	71.53
01:03 ET	300	71.42
01:06 ET	100	71.46
01:14 ET	375	71.39
01:17 ET	100	71.36
01:21 ET	1063	71.392
01:24 ET	968	71.38
01:26 ET	100	71.37
01:28 ET	394	71.42
01:30 ET	304	71.425
01:42 ET	100	71.46
01:44 ET	263	71.46
01:46 ET	600	71.475
01:48 ET	300	71.525
01:50 ET	100	71.56
01:51 ET	500	71.57
01:53 ET	449	71.48
01:55 ET	100	71.5
02:00 ET	100	71.47
02:02 ET	1007	71.44
02:06 ET	524	71.35
02:08 ET	300	71.44
02:09 ET	360	71.33
02:13 ET	100	71.38
02:15 ET	1345	71.375
02:18 ET	359	71.43
02:20 ET	100	71.43
02:22 ET	992	71.44
02:24 ET	100	71.44
02:26 ET	398	71.4255
02:27 ET	400	71.485
02:29 ET	600	71.45
02:33 ET	100	71.48
02:38 ET	100	71.5
02:40 ET	100	71.5
02:42 ET	300	71.5
02:44 ET	200	71.47
02:45 ET	945	71.47
02:51 ET	200	71.45
02:54 ET	200	71.44
02:56 ET	200	71.44
02:58 ET	400	71.44
03:00 ET	100	71.44
03:02 ET	229	71.41
03:03 ET	303	71.44
03:05 ET	500	71.43
03:07 ET	1229	71.32
03:12 ET	509	71.36
03:14 ET	407	71.35
03:16 ET	200	71.35
03:18 ET	1982	71.39
03:20 ET	1118	71.41
03:21 ET	1017	71.35
03:23 ET	200	71.3913
03:25 ET	100	71.375
03:27 ET	910	71.36
03:30 ET	200	71.361
03:32 ET	400	71.4
03:34 ET	715	71.44
03:36 ET	1513	71.385
03:38 ET	712	71.385
03:39 ET	823	71.35
03:41 ET	1494	71.38
03:43 ET	1100	71.375
03:45 ET	3421	71.32
03:48 ET	1200	71.39
03:50 ET	1334	71.37
03:52 ET	1941	71.293
03:54 ET	1395	71.28
03:56 ET	6525	71.34
03:57 ET	2545	71.36
03:59 ET	6400	71.36

Data delayed at least 15 minutes.

Jun 3, 2024
- Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities, from 1:05PM ET on Monday Jun 03, 2024 by Dow Jones
  1:05PM ET on Monday Jun 03, 2024 by Dow Jones
May 28, 2024
- Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America, from 9:53AM ET on Tuesday May 28, 2024 by Dow Jones
  9:53AM ET on Tuesday May 28, 2024 by Dow Jones
- *DJ Dr. Reddy's Laboratories Announces The Appointment Of Milan Kalawadia To CEO North America >RDY, from 9:53AM ET on Tuesday May 28, 2024 by Dow Jones
  9:53AM ET on Tuesday May 28, 2024 by Dow Jones
May 21, 2024
- Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia(R) & Xgeva(R) in the U.S., Europe and UK, from 10:05AM ET on Tuesday May 21, 2024 by Dow Jones
  10:05AM ET on Tuesday May 21, 2024 by Dow Jones
- Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia(R) & Xgeva(R) in the U.S., Europe and UK, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones
  8:00AM ET on Tuesday May 21, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesRDY Dr Reddy's Laboratories Ltd	11.6B	17.8x	+24.18%
United StatesMRNS Marinus Pharmaceuticals Inc	84.6M	-0.6x	---
United StatesMALG Microalliance Group Inc	36.6M	4.4x	---
United StatesCASI CASI Pharmaceuticals Inc	47.0M	-1.5x	---
United StatesEQ Equillium Inc	30.2M	-2.3x	---
United StatesBSEM Biostem Technologies Inc	124.2M	-85.5x	---
As of 2024-06-10

Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Contact Information

Headquarters: 8-2-337, Road No.3 Banjara HillsHYDERABAD, India 500034
Phone: 404-900-2900
Fax: 404-900-2999

Executives

Chairman of the Board: Kallam Reddy
Co-Chairman of the Board, Managing Director: Gunupati Prasad
Chief Executive Officer: Erez Israeli
Chief Financial Officer - Designate: Parag Agarwal
Chief Executive Officer, European Generics: Patrick Aghanian

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$11.6B
Revenue (TTM)	$3.3B
Shares Outstanding	166.5M
Dividend Yield	0.68%
Annual Dividend Rate	0.4826 USD
Ex-Dividend Date	07-28-23
Pay Date	08-11-23
Beta	0.54
EPS	$4.01
Book Value	$20.21
P/E Ratio	17.8x
Price/Sales (TTM)	3.5
Price/Cash Flow (TTM)	13.7x
Operating Margin	24.26%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Dr Reddy's Laboratories Ltd
NYSE:RDYUnited States

Search Criteria

Charts

Recent News

Jun 3, 2024

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities, from 1:05PM ET on Monday Jun 03, 2024 by Dow Jones

May 28, 2024

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America, from 9:53AM ET on Tuesday May 28, 2024 by Dow Jones

*DJ Dr. Reddy's Laboratories Announces The Appointment Of Milan Kalawadia To CEO North America >RDY, from 9:53AM ET on Tuesday May 28, 2024 by Dow Jones

May 21, 2024

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia(R) & Xgeva(R) in the U.S., Europe and UK, from 10:05AM ET on Tuesday May 21, 2024 by Dow Jones

Alvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia(R) & Xgeva(R) in the U.S., Europe and UK, from 8:00AM ET on Tuesday May 21, 2024 by Dow Jones

Pharmaceuticals - Diversified Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar